Ciaran Kohli-Lynch
@ceed.bsky.social
Health Economist @ Northwestern Med.
All views my own.
All views my own.
The polypill would lead to a net reduction in healthcare costs at annual prices below $443, and would remain high value at prices below $559.
January 22, 2025 at 6:51 PM
The polypill would lead to a net reduction in healthcare costs at annual prices below $443, and would remain high value at prices below $559.
Findings!
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
January 22, 2025 at 6:51 PM
Findings!
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
For a trial-representative cohort of 100,000 individuals, compared to usual care, polypill treatment:
- prevented 2,738 CVD events
- yielded 1,190 QALYs
- increased costs by ~$10,152,000
Hence, polypill treatment cost $8,560-per-QALY gained and was high value.
The American Heart Association considers treatments to be ‘high value’ if they cost less than $50,000-per-QALY gained. www.ahajournals.org/doi/10.1161/...
January 22, 2025 at 6:51 PM
The American Heart Association considers treatments to be ‘high value’ if they cost less than $50,000-per-QALY gained. www.ahajournals.org/doi/10.1161/...